摘要
目的探讨卡瑞利珠单抗联合放化疗在晚期宫颈癌(CCA)患者中的应用效果。方法选取2021年11月至2022年10月菏泽市牡丹人民医院收治的102例晚期CCA患者作为研究对象,按照随机数字表法分为对照组(51例)与研究组(51例)。对照组接受常规放化疗治疗,研究组在对照组基础上采用卡瑞利珠单抗治疗。比较两组临床疗效、肿瘤标志物[癌抗原125(CA125)、癌胚抗原(CEA)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]、细胞免疫功能及不良反应发生情况。结果研究组治疗总有效率高于对照组(P<0.05)。治疗后,与对照组相比,研究组CA125、CEA、CYFRA21-1水平更低(P<0.05)。治疗后,研究组CD8^(+)水平低于对照组,CD4^(+)、CD3^(+)水平高于对照组(P<0.05)。两组放射性膀胱炎、发热、贫血、骨髓抑制、消化道反应、放射性直肠炎及肝、肾功能异常的发生率比较,差异无统计学意义(P>0.05)。结论卡瑞利珠单抗联合放化疗用于晚期CCA患者的临床疗效确切,可降低肿瘤标志物水平,调节细胞免疫功能,且不增加不良反应,具有临床推广价值。
Objective To explore the application effect of Camrelizumab combined with radiotherapy and chemotherapy in patients with advanced cervical cancer(CCA).Methods A total of 102 patients with advanced CCA admitted to Mudan People’s Hospital in Heze City from November 2021 to October 2022 were selected as the study objects.All the patients were divided into the control group(51 cases)and the study group(51 cases)using the random number table method.The control group received routine radiotherapy and chemotherapy,while the study group received treatment with Camrelizumab on the basis of the control group.The clinical efficacy,tumor markers(cancer antigen 125[CA125],carcinoembryonic antigen[CEA],cyto-keratin 19 fragment antigen 21-1[CYFRA21-1]),cellular immune function,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,compared with the control group,the levels of CA125,CEA,and CYFRA21-1 in the study group were lower(P<0.05).After treatment,the level of CD8^(+)in the study group was lower than that in the control group,and the levels of CD4^(+)and CD3^(+)were higher than those in the control group(P<0.05).There was no difference in the incidence of radiationinduced cystitis,fever,anemia,myelosuppression,digestive tract reaction,radiation proctitis,and abnormal liver andkidney function between the two groups(P>0.05).Conclusion The clinical efficacy of Camrelizumab combined with radiotherapy and chemotherapy in patients with advanced CCA is definite,which can reduce levels of tumor markers,regulate cellular immune function,does not increase adverse re actions,and has clinical promotion value.
作者
朱琳
刘洁
ZHU Lin;LIU Jie(Department of Pharmacy,Mudan People’s Hospital in Heze City,Shandong Province,Heze 274000,China;Department of Obstetrics and Gynecology,Mudan People’s Hospital in Heze City,Shandong Province,Heze 274000,China)
出处
《妇儿健康导刊》
2024年第16期87-90,99,共5页
JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE
关键词
卡瑞利珠单抗
放化疗
晚期宫颈癌
Camrelizumab
Radiotherapy and chemotherapy
Advanced cervical cancer
